Every material Form 8-K Black Diamond Therapeutics, Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Black Diamond Therapeutics reported second-quarter 2026 results with a net loss of $9.9 million, narrowed from $10.6 million a year earlier. The company had no revenue in either quarter, and its six-month results swung to a net loss of $18.9 million from net income of $46.0 million in 2025, which included $70.0 million of license revenue. Cash, cash equivalents, and investments were $110.5 million at June 30, 2026, which the company says will fund operations into the second half of 2028.
Q2 2026 net loss was $9.9 million, compared with $10.6 million in Q2 2025.
Six-month net loss was $18.9 million, compared with net income of $46.0 million in the first half of 2025, which included $70.0 million of license revenue.
Cash, cash equivalents, and investments were $110.5 million at June 30, 2026, down from $128.7 million at December 31, 2025.
The company plans to provide an update on silevertinib's pivotal development path and FDA feedback in Q4 2026.
Black Diamond Therapeutics reported preliminary Phase 2 results for silevertinib in 43 frontline non-small cell lung cancer patients with EGFR non-classical mutations, showing a preliminary median progression-free survival of 15.2 months. The company said the data support a 150 mg daily dose for pivotal development and plans to meet with the FDA later this year to discuss its pivotal plan. The results are early and the study remains ongoing, so they do not establish approval prospects.
Preliminary median progression-free survival of 15.2 months; median duration of response not reached
Objective response rate of 60% by RECIST 1.1 and CNS objective response rate of 86%; no patients developed new brain metastases
Treatment-related adverse events above Grade 3 fell to 28% after dose reduction; 150 mg daily supported for pivotal development
Data to be presented by Julia Rotow, M.D., at ASCO on May 30, 2026; company webcast on May 21, 2026 at 5:30 p.m. EDT
Black Diamond Therapeutics reported a first-quarter 2026 net loss of $9.0 million, compared with net income of $56.5 million a year earlier. The company recorded no license revenue in the quarter, versus $70.0 million in the first quarter of 2025, and ended March 31, 2026 with $118.3 million in cash, cash equivalents and investments, which it says can fund operations into the second half of 2028.
No license revenue in Q1 2026 versus $70.0 million in Q1 2025
Net loss of $9.0 million ($0.16 per share) versus net income of $56.5 million ($1.00 per share basic) a year earlier
Cash, cash equivalents and investments of $118.3 million at March 31, 2026, down from $128.7 million at December 31, 2025
Oral presentation of silevertinib Phase 2 data scheduled for May 30, 2026 at the ASCO Annual Meeting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Black Diamond Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →